Researchers at Memorial Sloan Kettering Cancer Center identified clinically actionable germline mutations in 8.5 percent of about 2,700 unselected lung cancer patients.
A Memorial Sloan Kettering Cancer Center VP is giving the institute $1.4 million he made from representing it on a biotech board, the New York Times and ProPublica report.
Researchers find that fecal microbiome transplants restore gut bacteria in cancer patients who underwent antibiotic treatment for a stem cell transplant.
The tool, called Cerebro, significantly outperformed other publicly available methods, including in the less-trafficked areas of the genome that are now relevant for TMB immunotherapy prediction.
MSKCC investigators showed that truncated mRNAs can inactivate tumor suppressor genes, fueling cancer development even without the presence of DNA mutations.
